title: Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer.
abstract: BACKGROUND
  The utility of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) as prognostic factors in primary breast cancer is unclear.
  
  
  METHODS
  We prospectively studied CEA and CA 15.3 in the sera of 2062 patients with untreated primary breast cancer diagnosed between 1984 and 2008.
  
  
  RESULTS
  Increased CEA (>5 microg/L) and CA 15.3 (>30 kU/L) concentrations were found in 12.7% and 19.6% of the patients, respectively, and 1 or both tumor markers were increased in 28% (570 of 2062). Increases in each tumor marker correlated with larger tumor sizes and nodal involvement. Tumor size, estrogen receptor (ER), and CEA were independent prognostic factors by multivariate analysis in the total group [disease free survival (DFS) and overall survival (OS)] as well as in node-positive (NP) and node-negative (NN) patients. Nodal involvement and histological grade were independent prognostic factors in the total group as well as in NP patients. By contrast, adjuvant treatment and CA 15.3 were independent prognostic factors only in NN patients (DFS and OS). All patients with CEA >7.5 microg/L had recurrence during follow-up. Use of both tumor markers allowed discrimination of the groups of risk in T1 NN patients: 56.3% of recurrences were seen when 1 or both tumor markers were increased, whereas only 9.4% of recurrences were seen in T1 NN patients without increases of either marker.
  
  
  CONCLUSIONS
  CEA and CA 15.3 are useful prognostic factors in NP and NN breast cancer patients. CEA >7.5 microg/L is associated with a high probability of subclinical metastases.
authors.affiliation: Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clínic, Medical School, Barcelona, Spain. rmolina@clinic.ub.es
authors.forename: Rafael
authors.initials: R
authors.lastname: Molina
authors.forename: Jose M
authors.initials: JM
authors.lastname: Auge
authors.forename: Blanca
authors.initials: B
authors.lastname: Farrus
authors.forename: Gabriel
authors.initials: G
authors.lastname: Zanón
authors.forename: Jaume
authors.initials: J
authors.lastname: Pahisa
authors.forename: Montserrat
authors.initials: M
authors.lastname: Muñoz
authors.forename: Aureli
authors.initials: A
authors.lastname: Torne
authors.forename: Xavier
authors.initials: X
authors.lastname: Filella
authors.forename: Jose M
authors.initials: JM
authors.lastname: Escudero
authors.forename: Pedro
authors.initials: P
authors.lastname: Fernandez
authors.forename: Martin
authors.initials: M
authors.lastname: Velasco
mesh_terms: D000704:Analysis of Variance; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000097:blood / Q000175:diagnosis / Q000473:pathology; D002272:Carcinoembryonic Antigen / Q000097:blood*; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000175:diagnosis / Q000473:pathology; D018275:Carcinoma, Lobular / Q000097:blood / Q000175:diagnosis / Q000473:pathology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D018396:Mucin-1 / Q000097:blood*; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
chemical_list: D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone